Bart Clark, a professor of medicine at the Mayo Clinic and an investigator for the REPLACE study, cheered the results: “Considering hypoparathyroidism is the only endocrine disorder for which we do not have an approved replacement hormone to treat the underlying condition, these data indicate that Natpara may offer a valuable option to achieve a physiological treatment and outcome by delivering the missing hormone.”

MedCity News, Stephanie Baum, 11/8/11

Tags: Endocrinology / Diabetes